Parent-Child Interaction Therapy (PCIT) for Children With Traumatic Brain Injury (TBI): A Stepped-Care Model
Launched by UNIVERSITY OF MIAMI · Dec 21, 2023
Trial Information
Current as of July 27, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a special therapy called Parent-Child Interaction Therapy (PCIT) to help young children, aged 2 to 7, who have experienced a mild to moderate traumatic brain injury (TBI). The goal is to see how a step-by-step approach to this therapy can help improve behavior problems in these children. The study is not recruiting participants yet, but it aims to find out if this method can make a positive difference for families dealing with the effects of TBI.
To be eligible for the trial, children must be between 2 and 7 years old and have a mild to moderate TBI. The primary caregiver (the person taking care of the child) should be at least 18 years old and able to speak and read either English or Spanish. However, children and caregivers with major sensory impairments, like being deaf or blind, will not be included in the study. If selected, families can expect to participate in activities that focus on improving the child's behavior through engaging interactions, while also receiving support and guidance throughout the process.
Gender
ALL
Eligibility criteria
- Child Inclusion Criteria:
- • Child is between the ages of 2 and 7
- • Child has a mild to moderate TBI
- Primary Caregiver Inclusion Criteria:
- • Primary caregiver is 18 years or older
- • Primary caregiver speaks and reads in either English or Spanish
- Child Exclusion Criteria:
- • - Children with major sensory impairments (e.g., deafness, blindness)
- Primary Caregiver Exclusion Criteria:
- • - Primary caregiver with major sensory impairments (e.g., deafness, blindness)
About University Of Miami
The University of Miami, a leading academic institution, is dedicated to advancing medical research and improving patient care through innovative clinical trials. With a commitment to excellence in education and research, the university fosters collaboration among multidisciplinary teams to explore new therapies and treatment modalities. Its extensive clinical programs are supported by state-of-the-art facilities and a diverse patient population, enabling the exploration of cutting-edge solutions to complex health challenges. The University of Miami is poised to contribute significantly to the field of medicine through its rigorous scientific inquiry and a steadfast commitment to ethical research practices.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Miami, Florida, United States
Patients applied
Trial Officials
Dainelys Garcia, PhD
Principal Investigator
University of Miami
Jason F Jent, PhD
Principal Investigator
University of Miami
Jennifer Coto, PhD
Principal Investigator
University of Miami
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported